{"schema":"sb.node.v1","id":"sb:e/c20629a0b706193805a08f12","kind":"entity","label":{"text":"esmo","locale":"en"},"identity":{"anchor":"label:en:esmo","strength":"label"},"asOf":{"knowledgeCutoff":"2026-11-03T13:08:56.552092+00:00","releaseId":"sb-dbff8ce02881","snapshot":"deploy dccfd267181b1edc684d10eb59796f07a3cc2fa9"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":181,"separatePublishers":37,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"partial","share":0.448,"named":81,"of":181,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn only from rows whose own title or URL names the subject (the entity graph's subject gate)","blind":["only 45% of the 181 documents measured name the subject in their own text; the rest mention it in passing, so standing.evidence.supporting overstates coverage about it"]}},"admission":{"state":"canonical","kind":"receipted","kindBasis":"receipt-on-file","reason":"entity graph provenance 'curated'; promoted from the corpus by the machine rule; the promotion receipt (bars, evidence, snapshot) is on file but its contents are not yet served","policy":"promotion (receipt on file; contents not yet served)","admittedOn":"2026-10-14"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-04-14","to":"2026-11-02","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.061: about 94% of mentions carry no typed assertion"]}},"dimensions":{"domains":["biotech_pharma"],"activeDays":48,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"withheld":{"state":"withheld","count":1,"reason":"1 receipt withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/1a59e9144e6db7c8821e240e","kind":"observation","label":"European Medical Journal · 2026-11-01 · Targeted ADC Delays Progression in Relapsed Osteosarcoma: ESMO 2026","url":"https://www.emjreviews.com/oncology/news/targeted-adc-delays-progression-in-relapsed-osteosarcoma-esmo-2026/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/179c97e4dbd15f72adab2889","kind":"observation","label":"BioPharma Dive · 2026-10-30 · This week in charts: ESMO’s winners and losers","url":"https://www.biopharmadive.com/news/biotech-charts-esmo-2026-winners-losers/873281/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/27e628478dd20f58151566c7","kind":"observation","label":"Clinical Trials Arena · 2026-10-29 · Podcast: ESMO26: Major readouts from the 2026 congress","url":"https://www.clinicaltrialsarena.com/features/podcast-esmo26-major-readouts-from-the-2026-congress/","match":{"surface":"unknown","basis":"admitted by the entity graph's subject gate (title or URL), which does not record the surface; neither the headline nor the URL path names the subject by the door's on-topic test (the gate reads forms the door does not carry)"}},{"id":"sb:o/9978193065089a9c361f94fb","kind":"observation","label":"The Clinical Trial Vanguard · 2026-10-28 · Hengrui Pharma Presents 64 Studies at ESMO 2026, Record for Chinese Oncology Company","url":"https://www.clinicaltrialvanguard.com/news/hengrui-pharma-presents-64-studies-at-esmo-2026-record-for-chinese-oncology-company/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/a362aa0412a6336eaabb6a0c","kind":"observation","label":"The ASCO Post · 2026-10-28 · Esophageal Cancer Active Surveillance vs Standard Surgery After Neoadjuvant CRT","url":"https://ascopost.com/videos/esmo-congress-2026/esophageal-cancer-active-surveillance-vs-standard-surgery-after-neoadjuvant-crt/","match":{"surface":"url","basis":"admitted by the entity graph's subject gate (title or URL); the headline does not name the subject by the door's on-topic test, the URL path does"}},{"id":"sb:o/89caa3eae8ca9426d09cab13","kind":"observation","label":"The ASCO Post · 2026-10-28 · Advanced Biliary Tract Cancer Ivonescimab/Chemotherapy vs Durvalumab/Chemotherapy","url":"https://ascopost.com/videos/esmo-congress-2026/advanced-biliary-tract-cancer-ivonescimabchemotherapy-vs-durvalumabchemotherapy/","match":{"surface":"url","basis":"admitted by the entity graph's subject gate (title or URL); the headline does not name the subject by the door's on-topic test, the URL path does"}},{"id":"sb:o/26d81412a65e5c20e9e80c02","kind":"observation","label":"Endpoints News · 2026-10-27 · Outpace ends an ovarian cancer trial; Incyte data impresses at ESMO","url":"https://endpoints.news/outpace-ends-an-ovarian-cancer-trial-incyte-data-impresses-at-esmo/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/1a14eb231273c3f17b5e0d5f","kind":"observation","label":"European Medical Journal · 2026-10-27 · Moderna shares steady after ESMO data leak crash","url":"https://www.emjreviews.com/emj-gold/news/moderna-shares-steady-after-esmo-data-leak-crash/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/a06d2d1ee8291a582e82940e","kind":"observation","label":"European Medical Journal · 2026-10-27 · Ivonescimab Improves Survival in Biliary Tract Cancer: ESMO 2026","url":"https://www.emjreviews.com/oncology/news/ivonescimab-improves-survival-in-biliary-tract-cancer-esmo-2026/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/e8230269c299d5f10f7a85b8","kind":"observation","label":"Clinical Trials Arena · 2026-10-27 · ESMO26: Other skin cancer advances beyond groundbreaking cancer vaccine","url":"https://www.clinicaltrialsarena.com/news/esmo26-other-skin-cancer-advances-beyond-groundbreaking-cancer-vaccine/","match":{"surface":"unknown","basis":"admitted by the entity graph's subject gate (title or URL), which does not record the surface; neither the headline nor the URL path names the subject by the door's on-topic test (the gate reads forms the door does not carry)"}}],"cursor":"c1.eyJpZCI6InNiOmUvYzIwNjI5YTBiNzA2MTkzODA1YTA4ZjEyIiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTExLTAzVDEzOjA4OjU2LjU1MjA5MiswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity whose own title or URL (the entity graph's subject gate) names it; each says which in match. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with overall survival (83 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/a997eec85d84604ce2d57066"},{"kind":"relation","label":"co-mentioned with immunotherapy (81 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/8fa0fba4acde24192f20f19a"},{"kind":"relation","label":"co-mentioned with united states congress (64 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/385cf3727bb83f319b172439"},{"kind":"relation","label":"co-mentioned with lung cancer (63 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/702e5924677e9fdbaa10cc92"},{"kind":"relation","label":"co-mentioned with adverse events (57 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3c649418541345d5ac21a98b"},{"kind":"relation","label":"co-mentioned with spanish (57 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/624fc3a082e2bf198fb62fbd"},{"kind":"relation","label":"co-mentioned with clinical trial (48 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/45aee247bc18906393fa4af7"},{"kind":"relation","label":"co-mentioned with esmo congress (47 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e51c8c69981d0185cbfaa3c4"},{"kind":"relation","label":"co-mentioned with fda (43 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/5474804b05bb4aa532bca464"},{"kind":"relation","label":"co-mentioned with china (42 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/32bfb5adfb6da778b471f32b"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/c20629a0b706193805a08f12","mcp":"traverse {\"id\":\"sb:e/c20629a0b706193805a08f12\"}","page":"/entity/esmo/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/c20629a0b706193805a08f12\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/c20629a0b706193805a08f12\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"free-record","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/c20629a0b706193805a08f12\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"free-record","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/c20629a0b706193805a08f12\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"free-record","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history, which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"free-record","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"free-record","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"watch","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"watch","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"watch","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"watch","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"one-time-read","reason":"one-time Reads are not offered through this door; use ask"}]}